

GNI Group Ltd

Pharma & biotech

7 October 2014

Poised for the next phase

GNI is close to advancing its lead product Etuary (pirfenidone) into pivotal clinical studies in radiation pneumonitis, diabetic nephropathy and other fibrotic diseases. Etuary is commercialised in China for idiopathic pulmonary fibrosis (IPF). The company has global patents for Etuary, and for F351, its improved chemical entity, which is due to move into Phase II for liver fibrosis and potentially chronic kidney disease (CKD), both of which are prevalent in global populations. As GNI moves further forward, the scope to out-license these products in other territories, including the US, should improve.

Price **¥354**
Market cap **¥40bn**

Share price graph



Share details

Code 2160
Listing Tokyo Stock Exchange
Shares in issue 112.7m

Business description

GNI Group is a Japanese bio pharmaceutical company, with China-based drug discovery, development and manufacturing sites. Its pipeline includes proprietary anti-fibrotic Etuary and its derivative F351, in-licensed Tamibarotene (acute promyelocytic leukemia) and small molecule F573 (liver failure). GNI is expanding its pipeline, launching products initially for the Asian markets and with a view to seeking global deals.

Bull

- Track record of successful clinical development and commercialisation.
- Participation in emerging growth in non-traditional pharmaceutical market through a Japanese investment vehicle.
- Global out-licensing potential and broad pipeline.

Bear

- Relatively low profile outside Asia.
- Negative reputation of Chinese pharmaceutical industry.
- Chinese drug pricing is low and Chinese traditional medicine is still widespread.

Analysts

Emma Ulker +44 (0)20 3077 5738
Dr Mick Cooper +44 (0)20 3077 5734

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

From IND to NDA

To date, GNI has focused on the Chinese market, taking anti-fibrotic Etuary into orphan indications where few other clinical treatment options exist. GNI is advancing the product into Phase III studies in radiation pneumonitis initially for the Chinese market; it also holds global rights. GNI took Etuary, the only marketed therapy in China for IPF, from investigational new drug (IND) through to new drug application (NDA), one of few companies in China to complete the process. GNI also submitted an IND for the small molecule to the CFDA for diabetic nephropathy, the primary cause of mortality in young diabetics, targeting a direct move to Phase II.

Intercontinental growth potential

Having validated its capabilities, GNI is positioned for a new phase and it has CFDA approval to take F351, an improved chemical derivative of Etuary, into Phase II for liver fibrosis (the company estimates Chinese prevalence of c 18 million people). Subsequently it will develop F351 in CKD, initially in China but with options on global rights in these wider indications. GNI appears well placed to expand, both through growth in China and by forming international deals.

Multiple streams of revenue

Total H114 revenue increased 93.4% y-o-y to \$1.3m, including \$0.5m from Etuary sales launched in March plus CRO, licensing and manufacturing revenues. GNI had R&D expenses of c \$0.5m in H114. At the end of the period it held c \$45m cash and c \$3m in long-term convertible debt.

Valuation: Pharmaceutical style upside

GNI shares trade c 40% below the 12-month high despite a rebound triggered in late August by the reclassification of the company as a pharmaceutical rather than a services company. Potential medium-term catalysts, including the start of the approved Phase II trial of F351, granting of an import licence for Tamibarotene or clinical and commercial progress with Etuary, could drive a further re-rating.

Historic financials

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	2.0	(6.8)	(0.06)	0.0	N/A	N/A
12/13	1.9	(8.5)	(0.07)	0.0	N/A	N/A

Source: Bloomberg. Note: Converted from reported currency Japanese yen.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2014. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.